



Clinical trial results:

A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching From BRACET/Gilenya® to Natalizumab in Subjects With Relapsing Forms of Multiple Sclerosis (MS)

Summary

EudraCT number	2013-005586-39
Trial protocol	DE
Global end of trial date	04 November 2015

Results information

Result version number	v1 (current)
This version publication date	11 May 2017
First version publication date	11 May 2017

Trial information

Trial identification

Sponsor protocol code	101MS409
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02241785
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Biogen
Sponsor organisation address	225 Binney Street, Cambridge, Massachusetts, United States, 02142
Public contact	Biogen Study Medical Director, Biogen, clinicaltrials@biogen.com
Scientific contact	Biogen Study Medical Director, Biogen, clinicaltrials@biogen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	04 November 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	04 November 2015
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study is to determine the efficacy of natalizumab (Tysabri, BG00002) in participants with relapsing forms of multiple sclerosis (MS) who have failed Gilenya or BRACET (Betaseron, Rebif, Avonex, Copaxone, Extavia, Tecfidera) as measured by the proportion of participants with no evidence of disease activity (NEDA) at Year 1. The secondary objectives in this study population are: change in total T1 hypointense and total T2 hyperintense lesion volume; proportion of participants with NEDA at Year 2; evaluation of the impact of natalizumab on annualized relapse rate (ARR); and change in Multiple Sclerosis Impact Scale-29 (MSIS-29) physical impact score.

Protection of trial subjects:

Written informed consent was obtained from each subject prior to evaluations being performed for eligibility. Subjects were given adequate time to review the information in the informed consent and were allowed to ask, and have answered, questions concerning all portions of the conduct of the study. Through the informed consent process each subject was made aware of the purpose of the study, the procedures, the benefits and risks of the study, the discomforts and the precautions taken. Any side effects or other health issues occurring during the study were followed up by the study doctor. Subjects were able to stop taking part in the study at any time without giving any reason.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 September 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 47
Worldwide total number of subjects	47
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	47
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

The study included a 43-day screening period.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Natalizumab
------------------	-------------

Arm description:

natalizumab 300 mg intravenously (IV) every 4 weeks

Arm type	Experimental
Investigational medicinal product name	natalizumab
Investigational medicinal product code	BG00002
Other name	Tysabri
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received 1 open-label Tysabri 300 mg infusion every 4 weeks with the last dose planned to be administered at Week 104.

Number of subjects in period 1	Natalizumab
Started	47
Completed	0
Not completed	47
Consent withdrawn by subject	1
Adverse event, non-fatal	1
Sponsor Termination	43
Lost to follow-up	2

Baseline characteristics

Reporting groups

Reporting group title	Natalizumab
-----------------------	-------------

Reporting group description:

natalizumab 300 mg intravenously (IV) every 4 weeks

Reporting group values	Natalizumab	Total	
Number of subjects	47	47	
Age categorical			
Units: Subjects			
Adults (18-64 years)	47	47	
Age Continuous			
Units: years			
arithmetic mean	41.9		
standard deviation	± 10.43	-	
Gender, Male/Female			
Units: Subjects			
Female	34	34	
Male	13	13	

End points

End points reporting groups

Reporting group title	Natalizumab
Reporting group description: natalizumab 300 mg intravenously (IV) every 4 weeks	

Primary: Proportion of Subjects With No Evidence of Disease Activity (NEDA) From Reset Baseline (Week 8) to Week 56

End point title	Proportion of Subjects With No Evidence of Disease Activity (NEDA) From Reset Baseline (Week 8) to Week 56 ^[1]
-----------------	---

End point description:

The proportion of subjects with NEDA, defined as follows: no Expanded Disability Status Scale (EDSS) progression (12-week sustained); no relapses; no gadolinium enhancing (Gd+) lesions; no new or enlarging T2 hyperintense lesions over 48 weeks after resetting the Baseline at Week 8 to remove contribution of combined unique active (CUA) lesions that occurred prior to Week 8, when natalizumab was not yet active. The EDSS quantifies disability in 8 functional systems. The final EDSS score is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.

The limited number of subjects enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis.

End point type	Primary
----------------	---------

End point timeframe:

Reset Baseline (Week 8) to Week 56

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The limited number of subjects enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis.

End point values	Natalizumab			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[2]			
Units: proportion of subjects				

Notes:

[2] - Efficacy data not collected and outcomes not analyzed, as per the pre-specified plan of analysis.

Statistical analyses

No statistical analyses for this end point

Secondary: Change in T1 Unenhancing Lesion Volume and T2 Lesion Volume From Baseline (Day -1) to Reset Baseline (Week 8)

End point title	Change in T1 Unenhancing Lesion Volume and T2 Lesion Volume From Baseline (Day -1) to Reset Baseline (Week 8)
-----------------	---

End point description:

As measured by magnetic resonance imaging.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day -1) to Reset Baseline (Week 8)

End point values	Natalizumab			
Subject group type	Reporting group			
Number of subjects analysed	43			
Units: cc				
arithmetic mean (standard deviation)				
Change in T1 Unenhancing Lesion Volume	0.11 (± 0.65)			
Change in T2 Lesion Volume	0.01 (± 1.76)			

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With NEDA From Week 8 (Reset Baseline) to Week 104

End point title	Proportion of Subjects With NEDA From Week 8 (Reset Baseline) to Week 104
-----------------	---

End point description:

Proportion of subjects with NEDA from Week 8 (Reset Baseline) to Week 104 (with no 12-week confirmed EDSS progression determined at Week 116). NEDA was defined as follows: no EDSS progression (12-week sustained); no relapses; no Gd+ lesions; no new or enlarging T2 hyperintense lesions over 48 weeks after resetting the Baseline at Week 8 to remove contribution of CUA lesions that occurred prior to Week 8, when natalizumab was not yet active. The EDSS quantifies disability in 8 functional systems. The final EDSS score is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.

The limited number of subjects enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

from Week 8 (Reset Baseline) to Week 104

End point values	Natalizumab			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[3]			
Units: proportion of subjects				

Notes:

[3] - Efficacy data not collected and outcomes not analyzed, as per the pre-specified plan of analysis.

Statistical analyses

No statistical analyses for this end point

Secondary: Pre- and Post-Natalizumab Infusion Annualized Relapse Rate (ARR) Comparison at Month 12

End point title	Pre- and Post-Natalizumab Infusion Annualized Relapse Rate (ARR) Comparison at Month 12
End point description: An MS relapse was defined as the onset of new or recurrent neurological symptoms lasting at least 24 hours, accompanied by new objective abnormalities on a neurological examination, and not explained solely by non-MS processes such as fever, infection, severe stress, or drug toxicity. 95% confidence interval is based on a Poisson regression model.	
End point type	Secondary
End point timeframe: From 12 months prior to natalizumab infusion and 12 months post-natalizumab infusion	

End point values	Natalizumab			
Subject group type	Reporting group			
Number of subjects analysed	47			
Units: relapses per subject-year				
number (confidence interval 95%)				
12 months pre-natalizumab infusion	1.553 (1.306 to 1.847)			
12 months post-natalizumab infusion	0.159 (0.076 to 0.331)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change in MSIS-29 Physical Impact Scores from Baseline (Day -1) to Reset Baseline (Week 8)

End point title	Change in MSIS-29 Physical Impact Scores from Baseline (Day -1) to Reset Baseline (Week 8)
End point description: The MSIS-29 is a brief self-administered MS-specific instrument measuring physical (20 items) and mental/psychological (9 items) impact of MS. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health.	
End point type	Secondary
End point timeframe: Baseline (Day -1) to Reset Baseline (Week 8)	

End point values	Natalizumab			
Subject group type	Reporting group			
Number of subjects analysed	45			
Units: units on a scale				
arithmetic mean (standard deviation)	-2.53 (± 12.42)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

From Screening through end of study. Duration of study treatment was up to 13 months.

Adverse event reporting additional description:

SAEs only were collected. Events were not coded by MedDRA.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	events not coded
-----------------	------------------

Dictionary version	0
--------------------	---

Reporting groups

Reporting group title	Natalizumab
-----------------------	-------------

Reporting group description:

natalizumab 300 mg IV every 4 weeks

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: The limited number of subjects enrolled and the early termination of the study resulted in serious adverse events data only being collected, as per the pre-specified plan of analysis.

Serious adverse events	Natalizumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 47 (4.26%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Nervous system disorders			
Syncopal episode			
subjects affected / exposed	1 / 47 (2.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	1 / 47 (2.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Natalizumab		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 47 (0.00%)		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 July 2014	The primary reasons for this amendment are to amend the term "free(dom) from measured disease activity (FMDA)" to "no evidence of disease activity (NEDA)", to allow sufficient time for MRI scan processing and determination of acceptability prior to Tysabri dosing, and to update procedures for the EDSS examination. In addition, minor revisions were made to study procedures to either clarify procedures or for consistency with other study procedures.
12 August 2014	The primary reason for this amendment is to correct the version number listed on the Synopsis of the previous version.
29 October 2014	The primary reasons for this amendment are to remove the MS cognition composite battery assessments from the protocol, add the time period for the natalizumab infusion, change the number of participating sites from 50 to 30, revise the number of subjects from 200 to 130, revise the number of subjects in the exploratory DTI substudy from 70 to 50, revise the inclusion criteria for lymphocytes to be at or above the lower limit of normal instead of within the normal limits (the LLN value is also provided), revise the exclusion criteria to exclude Tysabri "or any of its ingredients".
23 July 2015	The primary reason for this amendment is to reduce the time required for subjects to have been on Gilenya® or BRACET at Screening and to increase the period during which disease activity can be observed prior to Screening for entry into the study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

As a result of early study termination and limited available data, no meaningful conclusions can be drawn.

Notes: